Though primary multiple sclerosis-related fatigue (PMSF) affects more than 70 percent of multiple sclerosis (MS) patients, there are limited pharmacological treatment options, and as of yet, no drug has been specifically approved by the U.S. Food and Drug Administration for the treatment of PMSF.

Biopharmaceutical company MultiCell Technologies Inc. (MCET.OB) today announced it will retain Clinical Development & Support Services Ltd. (CDSS) of Cheshire, England to manage its planned phase IIb clinical trial in the UK for MCT-125, MultiCell’s lead drug candidate for treatment of PMSF.

MCT-125 is a fixed dose, orally administered combination thought to lead decrease fatigue levels in persons with MS.

In previous phase IIa studies, MCT-125 was tested on 138 patients suffering from PMSF. Results showed efficacy within four weeks of administration, proving to be active across all severity levels and sub-types of multiple sclerosis.

CDSS offers an array of clinical development services to the pharmaceutical, biotechnology and medical device industries, specializing in the management of clinical trials. Its services cover all phases of clinical development, from the first administration of drugs in humans through to post-marketing studies.

Shares of MultiCell surged nearly 8 percent to $0.0097 in today’s mid-day trading following the morning’s press release.

For more information on the company, visit